Genmab
GMAB
219 hedge funds and large institutions have $1.28B invested in Genmab in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 66 reducing their positions, and 41 closing their positions.
63% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $9.44M
39% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 66
6.18% more ownership
Funds ownership: 91.86% → 98.04% (+6.2%)
1% more capital invested
Capital invested by funds: $1.27B → $1.28B (+$10.3M)
10% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 41
4% less funds holding
Funds holding: 228 → 219 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$60.7M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$28.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$28M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$22.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$53.4M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$41.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.9M |
| 4 |
BlackRock
New York
|
-$14.3M |
| 5 |
BM
Bridger Management
New York
|
-$6.08M |
GMAB Hedge Fund Activity: Q1 2025 in Review
219 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2025, worth a combined $1.28B — up 0.81% from $1.27B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of GMAB and 37 opened new positions — a net loss of 4 holders — while 66 trimmed existing stakes and 92 added.
The largest buyer was Orbis Allan Gray, adding an estimated $60.7M. The largest seller was Capital International Investors, exiting entirely with an estimated $53.4M sold.
- 219 institutional investors held Genmab (GMAB) as of Q1 2025, down from 228 in Q4 2024.
- Funds reported $1.28B of Genmab stock for Q1 2025, up 0.81% quarter-over-quarter.
- 37 funds opened new Genmab positions in Q1 2025 and 41 closed out, a net change of -4 holders.
- The largest Genmab buyer in Q1 2025 was Orbis Allan Gray, an estimated $60.7M added.
- The largest Genmab seller in Q1 2025 was Capital International Investors, an estimated $53.4M sold.
Based on aggregated 13F filings for Q1 2025.